Barely Significant
← all excerpts

Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial.

Signal Transduct Target Ther · 2023 · PMC10115841 · PMID 37076476

Europe PMCDOI
1
hedged sentence
0.0600
closest p · 1.2× alpha
0.0600
boldest claim

The sentences

borderline significantP = 0.06so close (0.05 < p ≤ 0.1)
The repeated measures of ANOVA revealed the saxagliptin plus vitamin D group was significantly different compared with the conventional therapy group ( P = 0.001), and the full least-squares models indicated a significant difference of mean change of 2-h C-peptide AUC between the saxagliptin plus vitamin D group and the conventional therapy group at 12 months, 18 months and 24 months ( P = 0.023, 0.038 and 0.013, respectively), and a borderline significant difference at 6 months ( P = 0.06).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.